R&D | March 17, 2026
Samsung Biologics, Eli Lilly team up to launch major biotech hub in Korea
The planned facility, to be built at Samsung’s Bio Campus II, is set to become a launchpad for up to 30 emerging biotech firms
The planned facility, to be built at Samsung’s Bio Campus II, is set to become a launchpad for up to 30 emerging biotech firms
FGFR alterations are prevalent in early-stage bladder cancer, appearing in roughly 70% of intermediate-risk and 40% of high-risk NMIBC tumors
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
COVIRIX Medical says its broad-spectrum antiviral portfolio has already shown positive virology results against key pandemic threats
Under the agreement, healthcare professionals in the country will gain access to C2N’s PrecivityAD2 blood test
The expanded ownership is expected to improve access to Cialis for millions of men in Asia affected by ED and BPH
There are limited treatment options available for patients living with non-diabetic CKD, and the unmet need is high for new treatments to delay kidney disease progression and reduce cardiovascular risk
Cadila Pharmaceuticals’ journey has been marked by several milestones, including the development of indigenous formulations, expansion into global markets, and the creation of robust manufacturing and R&D capabilities
The facility will manufacture the critical antibiotic intermediate Amino Cephalosporanic Acid (ACA), a key component in the production of cephalosporin antibiotics
Subscribe To Our Newsletter & Stay Updated
